SABCS and AACR award scholarships to budding early-career researchers


Estimated Read Time:

5 minutes

The San Antonio Breast Cancer Symposium (SABCS) and its co-sponsor the American Association of Cancer Research (AACR), award scholarships every year to researchers to help their work be seen. The researchers are typically early in their career.

Following is the list of this year’s scholarship winners and the research topics they will present this week at SABCS 2021.

For laboratory-based investigators-in-training whose work focuses on the biology of breast cancer and preclinical models of its development and progression.

William M. Tahaney, PhD, The University of Texas MD Anderson Cancer Center, Houston
Inhibition of GPX4 induces preferential death of p53-mutant triple-negative breast cancer cells
GS1-09, Tuesday, Dec. 7, 10:15 am CT

Priyanka S. Rana, PhD, The MetroHealth System, Case Western Reserve University, Cleveland
Targeted deletion of Kindlin-2 in mouse mammary glands inhibits tumor growth, invasion and metastasis downstream of TGF-β/EGF oncogenic signaling pathway
P1-06-02, Wednesday, Dec. 8, 7:00 am CT

Priya Bhardwaj, BA, Weill Cornell Medicine, New York
Obesity is associated with DNA damage in the breast epithelium of BRCA1 and BRCA2 mutation carriers: A role for estrogens & strategies for prevention
P2-06-03, Wednesday, Dec. 8, 5:00 pm CT

Lisa D. Cervia, PhD, Dana-Farber Cancer Institute and Broad Institute of MIT and Harvard, Boston
A ubiquitination cascade regulating the integrated stress response and survival in carcinomas
P3-09-01, Thursday, Dec. 9, 7:00 am CT

Svetlana E. Semina, PhD, University of Illinois at Chicago (UIC), Dept. of Physiology and Biophysics, College of Medicine, Chicago
Identification of novel ER and ER-NFκB driven stem-like cell populations in ER+ breast cancer
P5-11-01, Friday, Dec. 10, 7:00 am CT

For clinical scientists-in-training who are actively pursuing clinical or clinical/translational research in breast cancer.

Beverly Kyalwazi, BS, University of Chicago Pritzker School of Medicine, Chicago
Analysis of clinical outcomes and expression-based immune signatures by race in the I-SPY 2 trial
GS4-02, Friday, Dec. 10, 9:00 am CT

Anton Safonov, MD, Memorial Sloan Kettering Cancer Center, New York
Comprehensive genomic profiling of patients with breast cancer identifies germline-somatic interactions mediating therapy resistance
GS4-08, Friday, Dec. 10, 10:30 am CT

Daniel L. Abravanel, MD, PhD, Dana-Farber Cancer Institute, Boston
Spatio-molecular dissection of the breast cancer metastatic microenvironment
PD6-03 Wednesday, Dec. 8, 5:00 pm CT

Sasha R. Douglas, MD, UC San Diego, La Jolla, Calif.
Trends in surgical resection for stage IV breast cancer: Less surgery more systemic treatment
PD7-06, Thursday, Dec. 9, 7:00 am CT

Ramsha Iqbal, MD, Amsterdam UMC, Noord-Holland, Netherlands
Towards a new standard for staging: A comparative study of [18F]FES PET/CT vs [18F] FDG PET/CT in patients with clinical stage II/III and locoregional recurrent estrogen receptor positive breast cancer
P3-02-11, Thursday, Dec. 9, 7:00 am CT


In memory of Dr. Charles A. Coltman, co-founder of SABCS, to commemorate the significant contributions he made to oncology medicine. For clinical scientists-in-training.

André Pfob, MD, Heidelberg University Hospital, Heidelberg, Germany
Intelligent vacuum-assisted breast biopsy to identify breast cancer patients with pathologic complete response after neoadjuvant systemic treatment for omission of breast and axillary surgery
PD7-02, Thursday, Dec. 9, 7:00 am CT

Milana Arantza Bergamino Sirvén, MD, The Institute of Cancer Research, London
HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer
PD15-02, Friday, Dec. 10, 7 am CT

Whitney L. Hensing, MD, MSCR, Washington University in St. Louis, St. Louis, Mo.
Genetic alterations detected by circulating tumor DNA (ctDNA) in HER2-low metastatic breast cancer (MBC)
P2-01-01, Wednesday, Dec. 8, 5:00 pm CT

Ha-Linh Nguyen, MS, KU Leuven, Leuven, Belgium
The association between genomic alterations and body mass index in patients with early breast cancer
P3-09-18, Thursday, Dec. 9, 7:00 am CT

Cheng Peng, ScD, Brigham and Women’s Hospital, Harvard Medical School, Boston
Regular aspirin use, breast tumor characteristics, and long-term breast cancer survival
P3-12-01, Thursday, Dec. 9, 7:00 am CT


For presenters of meritorious abstracts who are Associate Members of the American Association for Cancer Research (AACR).

Lixuan Wei, PhD, Mayo Clinic, Rochester, MN
Estrogen receptor is a target of enzalutamide in ER+ breast cancer
PD1-03, Wednesday, Dec. 8, 7:00 am CT

Gun Min Kim, MD, UT Southwestern Simmons Cancer Center, Dallas
Combined inhibition of CDK4/6 and AKT is effective in Rb-intact triple-negative breast cancer of the luminal androgen receptor (LAR) subtype
PD3-07, Wednesday, Dec. 8, 7:00 am CT

Alexa Glencer, MD, University of California San Francisco, San Francisco
The tumor immune microenvironment and HER2 landscape of high-risk ductal carcinoma in situ: The DEFENSE study
P1-05-01, Wednesday, Dec. 8, 7:00 am CT

Yuxi Liu, MS, Harvard T.H. Chan School of Public Health, Boston
A genome-wide association study of mammographic texture variation
P3-13-02, Thursday, Dec. 9, 7:00 am CT

Hsiao-Ching Huang, MPH, University of Illinois at Chicago, College of Pharmacy, Department of Pharmacy, Systems, Outcomes and Policy (PSOP), Chicago
Racial/ethnic differences in the benefit of adjuvant chemotherapy for breast cancer patients with an intermediate risk 21-gene recurrence score
P3-14-02, Thursday, Dec. 8, 7:00 am CT

Zhengyi Deng, MS, Johns Hopkins Bloomberg School of Public Health, Baltimore
Racial/ethnic disparities in cancer mortality after a second breast cancer
P3-14-05, Thursday, Dec. 9, 7:00 am CT

Arnaldo Andres Marin Valdes, MD, UT Southwestern Simmons Comprehensive Cancer Center, Dallas
A spectrum of secondary mutations in HER2 augment breast cancer cell growth and reduce neratinib sensitivity in HER2-mutant breast cancer
P4-01-02, Thursday, Dec. 9, 5:00 pm CT

Yihao Li, PhD, Dana-Farber Cancer Institute, Boston
FGFR inhibitor mediated dismissal of SWI/SNF complexes from YAP-dependent enhancers induces therapeutic resistance in triple negative breast cancer
P4-01-04, Thursday, Dec. 9, 5:00 pm CT

Adam Dunn Officer, BS, University of California San Diego, San Diego
A gene expression meta-analysis identifies microenvironment differences in cellular composition and cell-cell interactions associated with breast cancer invasion
P5-06-02, Friday, Dec. 10, 7:00 am CT

Lan Thi Hanh Phi, MS, MD Anderson Cancer Center UT Health Graduate School of Biomedical Sciences, Houston
TBK1 inhibition potentiates the efficacy of AXL-targeted therapy in aggressive breast cancer preclinical models
P5-08-10, Friday, Dec. 10, 7:00 am CT